162 related articles for article (PubMed ID: 34951137)
1. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort.
Simon D; Tascilar K; Kleyer A; Fagni F; Krönke G; Meder C; Dietrich P; Orlemann T; Kliem T; Mößner J; Liphardt AM; Schönau V; Bohr D; Schuster L; Hartmann F; Leppkes M; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Atreya R; Berking C; Sticherling M; Neurath MF; Schett G
Arthritis Rheumatol; 2022 May; 74(5):783-790. PubMed ID: 34951137
[TBL] [Abstract][Full Text] [Related]
2. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
van Dam KPJ; Volkers AG; Wieske L; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Cristianawati O; Ten Brinke A; Verstegen NJM; van Ham SM; Rispens T; Kuijpers TW; Löwenberg M; Eftimov F;
BMC Infect Dis; 2023 May; 23(1):332. PubMed ID: 37198536
[TBL] [Abstract][Full Text] [Related]
3. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases.
Romero-Bogado L; Steiner M; Thuissard Vasallo IJ; Andreu Vázquez C; Navío T; Muñoz-Fernández S;
Med Clin (Barc); 2024 May; 162(10):470-476. PubMed ID: 38418311
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.
Geldof J; Truyens M; Sabino J; Ferrante M; Lambert J; Lapeere H; Hillary T; Van Laethem A; de Vlam K; Verschueren P; Padalko E; Lobaton T; Vermeire S
Front Immunol; 2023; 14():1126351. PubMed ID: 36936974
[TBL] [Abstract][Full Text] [Related]
5. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).
Tran AP; Tassone D; Nossent J; Ding NS
RMD Open; 2022 May; 8(1):. PubMed ID: 35577478
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
[TBL] [Abstract][Full Text] [Related]
7. Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases.
Mrak D; Kartnig F; Sieghart D; Simader E; Radner H; Mandl P; Göschl L; Hofer P; Deimel T; Gessl I; Kain R; Winkler S; Smolen JS; Perkmann T; Haslacher H; Aletaha D; Heinz LX; Bonelli M
J Autoimmun; 2023 Feb; 135():102981. PubMed ID: 36706534
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease.
Haberman RH; Herati RS; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy S; Neurath M; Abramson SB; Schett G; Mulligan MJ; Scher JU
medRxiv; 2021 May; ():. PubMed ID: 34013285
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases.
Petrone L; Picchianti-Diamanti A; Sebastiani GD; Aiello A; Laganà B; Cuzzi G; Vanini V; Gualano G; Grifoni A; Ferraioli M; Castilletti C; Meschi S; Vaia F; Nicastri E; Sette A; Goletti D
Int J Infect Dis; 2022 Aug; 121():24-30. PubMed ID: 35462039
[TBL] [Abstract][Full Text] [Related]
10. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.
Al-Janabi A; Ra A; Littlewood Z; Foulkes AC; Hunter HJA; Chinoy H; Moriarty CA; Hyrich KL; Limdi JK; Yiu ZZN; Griffiths CEM; Warren RB
Br J Dermatol; 2023 Mar; 188(4):542-551. PubMed ID: 36695406
[TBL] [Abstract][Full Text] [Related]
11. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.
Simon D; Tascilar K; Krönke G; Kleyer A; Zaiss MM; Heppt F; Meder C; Atreya R; Klenske E; Dietrich P; Abdullah A; Kliem T; Corte G; Morf H; Leppkes M; Kremer AE; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Maier C; Hueber AJ; Manger K; Manger B; Berking C; Tenbusch M; Überla K; Sticherling M; Neurath MF; Schett G
Nat Commun; 2020 Jul; 11(1):3774. PubMed ID: 32709909
[TBL] [Abstract][Full Text] [Related]
12. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
[TBL] [Abstract][Full Text] [Related]
13. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
[TBL] [Abstract][Full Text] [Related]
14. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
Front Immunol; 2021; 12():781843. PubMed ID: 34956211
[TBL] [Abstract][Full Text] [Related]
15. Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.
Minopoulou I; Tascilar K; Corte G; Mutlu MY; Schmidt K; Bohr D; Hartmann F; Manger K; Manger B; Korn K; Kleyer A; Simon D; Harrer T; Schett G; Fagni F
Rheumatology (Oxford); 2024 May; 63(5):1377-1383. PubMed ID: 37531288
[TBL] [Abstract][Full Text] [Related]
16. Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.
Koehm M; Klippstein M; Dauth S; Hallmann K; Kohmer N; Burkhardt H; Ciesek S; Geisslinger G; Rabenau HF; Behrens F
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37652553
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Stalman EW; Wieske L; van Dam KPJ; Kummer LY; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; Van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng OYK; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; Van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; Rispens T; van Ham SM; Kuijpers TW; Eftimov F;
Ann Rheum Dis; 2022 Dec; 81(12):1757-1766. PubMed ID: 36357161
[TBL] [Abstract][Full Text] [Related]
19. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Seroconversion in Children and Adults With Mild COVID-19.
Toh ZQ; Anderson J; Mazarakis N; Neeland M; Higgins RA; Rautenbacher K; Dohle K; Nguyen J; Overmars I; Donato C; Sarkar S; Clifford V; Daley A; Nicholson S; Mordant FL; Subbarao K; Burgner DP; Curtis N; Bines JE; McNab S; Steer AC; Mulholland K; Tosif S; Crawford NW; Pellicci DG; Do LAH; Licciardi PV
JAMA Netw Open; 2022 Mar; 5(3):e221313. PubMed ID: 35262717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
